You are here

FDA Panel Backs Subcutaneous Rituximab / Hyaluronidase Combo for Lymphoma and Leukemia

Approval decision scheduled for June

The FDA’s Oncologic Drugs Advisory Committee has voted unanimously (11 to 0) that the risk–benefit ratio of rituximab/hyaluronidase for subcutaneous (SC) injection (Halozyme Therapeutics) was favorable for patients in the proposed indications of follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia. The FDA action date is June 26, 2017.

Upon approval, subcutaneous rituximab could reduce the administration time for the rituximab portion of patients’ treatment to five to seven minutes compared with an hour and a half or more for intravenous administration, according to Halozyme.

Rituximab coformulated with recombinant human hyaluronidase was approved in Europe in 2014 and is currently marketed as the SC formulation of MabThera (rituximab) in approximately 50 countries worldwide.

Source: Halozyme Therapeutics; March 29, 2017.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation